Blue Jet Healthcare Q1 Results Total Revenue ₹162.90 crores & Operating Income ₹40.78 crores

Blue Jet Healthcare Q1 Results: Blue Jet Healthcare's Q1 results show several important changes in their financial performance. The total revenue for June 2024 was ₹162.90 crores, which is a quarter-on-quarter (QoQ) decrease of 11.44% from ₹720.98 crores in March 2023. Comparing this to the same period last year, the revenue also declined by 9.27% from ₹179.54 crores, indicating challenges in generating sales.

Blue Jet Healthcare’s selling, general, and administrative (SG&A) expenses increased by 4.67% QoQ, but were up 16.05% compared to June 2023. This suggests that the company is spending more on operations. The depreciation and amortization expenses significantly dropped by 54.88% QoQ, and also decreased by 42.44% year-over-year (YoY), indicating a reduction in asset values.

Blue Jet Healthcare’s total operating expenses decreased by 11.89% QoQ and 3.57% YoY. However, the company reported an operating income of ₹40.78 crores, down 10.07% QoQ and 22.92% YoY. The net income before taxes also fell by 8.64% QoQ and 14.60% YoY. Lastly, the diluted normalized EPS declined by 4.80% QoQ and 14.30% YoY, reflecting lower earnings per share compared to previous quarters.

Here's a simple summary of Blue Jet Healthcare's Q1 results:

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Blue Jet Healthcare Q1 Results

Blue Jet Healthcare released its financial results for the quarter ending June 30, 2024. The company earned about 1,628.99 million in revenue from its operations, which is lower than the previous quarter’s revenue of 1,839.45 million. They also made 87.15 million from other income, bringing their total income to 1,716.14 million. However, their expenses were high, totaling 1,221.45 million, which includes costs for materials, employee benefits, and other expenses. This means their profit before tax was 494.69 million, which shows a decrease compared to earlier quarters.

Blue Jet Healthcare After paying taxes of 116.92 million, their profit for this period was 371.77 million. The earnings per share (EPS) remained steady at 2.18 for both basic and diluted shares. Overall, while the revenue decreased, the company still made a profit, but it was lower than in previous periods. This indicates some challenges, yet they continue to maintain a positive financial standing. The numbers suggest that Blue Jet Healthcare is managing its operations, but they need to address the decline in revenue to improve their financial performance in the future.

Here’s a simplified summary of the financial results for Blue Jet Healthcare for the quarter ended June 30, 2024:

(in millions)

Blue Jet Healthcare Financial Metrics

Blue Jet Healthcare is a company with a market capitalization of ₹9,040 crore, meaning this is the total value of all its shares combined. Its current stock price is ₹521. The highest price it has reached recently is ₹547, while the lowest is ₹319. The Price-to-Earnings (P/E) ratio is 55.0, indicating investors are willing to pay ₹55 for every ₹1 of earnings. The book value per share is ₹48.7, which reflects the company's net worth per share. 

Here's the financial data presented in a simple table format:

Quarterly Results 

The Blue Jet Healthcare table for Dec 2023, Mar 2024, and Jun 2024 shows key financial figures. In December 2023, the company had sales of 167 crores and expenses of 112 crores, resulting in an operating profit of 55 crores. By March 2024, sales increased to 184 crores, but expenses rose to 131 crores, leading to a slightly lower operating profit of 53 crores. In June 2024, sales dropped to 163 crores, and expenses were 119 crores, causing the operating profit to fall to 44 crores.

Here’s the table for Dec 2023, Mar 2024, and Jun 2024:

(Standalone Figures in Rs. Crores)

About Blue Jet Healthcare 

Blue Jet Healthcare has a rich history of 53 years in the healthcare industry. It began with Jet Chemicals, founded by Late Shri B. L. Arora in 1968, as the first manufacturer of saccharin in India. Over the years, the company expanded its capabilities, entering the X-Ray contrast media business in 1997 and becoming India's largest producer of saccharin by 2009. In 2019, it merged two sister companies to create Blue Jet Healthcare.

Blue Jet Healthcare focuses on sustainable practices, including wastewater recycling, and has a USFDA-approved facility. Strategic acquisitions, such as new sites in Mahad and Ambernath, have allowed it to scale up production of pharmaceuticals and intermediates. Blue Jet Healthcare is committed to delivering high-quality products and building strong relationships with multinational customers. Its headquarters is in Mumbai, India.